NervGen Pharma is a clinical-stage biotechnology enterprise dedicated to developing innovative treatments for nervous system damage. Its core scientific focus centers on repairing nerve damage resulting from traumatic injuries and chronic neurodegenerative diseases, most notably through its proprietary lead therapeutic candidate, NVG-291, which aims to promote nerve regeneration and functional recovery.